

Innovative Approaches Working Group Universal Team-Based Learning Activity Exercise 3 Whole-Genome Sequencing

Objectives: By the end of the session, you will be able to:

- 1. Describe key aspects of informed consent for genomic analyses
- 2. Describe the process of NGS-data analysis
- 3. Describe the reporting issues related to incidental findings
- 4. Use online tools to interpret the clinical significance of genomic data

Team-based Learning Activity:

Case Presentation

The gene panel test that was ordered does not demonstrate a variant that can explain the patient's diagnosis of ______. The patient decides to enroll in a study, similar to the 1000 Genomes Project, that will perform whole genome analysis on a blood sample.

- 1. List 3 key components in the informed-consent process for whole-exome and wholegenome sequencing studies. (REVEAL) (10 minutes)
- 2. You are asked to specifically review sequencing data to determine whether to call and report specific variants (see the following images; image 1 represents one variant and image 2 represents another variant). (20 minutes)


The variants below are from the original exercise. We would need to find others that could be used that still illustrate the key points in a gene related to the patient's disease or we could perhaps relabel these but real data would be best.

- a. List 3 criteria you would you use to call a variant. (REVEAL)
- b. List 2 criteria you would use to report a variant. (REVEAL)



Genomes View Tracks Regions Tools	GenomeSpace Help		IGV.		# E & • 🖏 🔿 † 🔺 •	Thu Jan 30 3:10 PM Q I
10.89,725,255-89,725,	333 Go 🔮 🖣	• 🗢 🗖 × 🖻	1.10			
	2 9121 91122 8.75.75w	9114 91121 91122	4213 4212 4213 8.15.29 to 10.15	4723 4722 4723 4733 4	8.763.11 (24.1) (25.1) (25.2) (25.2) 8.763.11 (20.1) (20.1	ອດ <u>1</u> ອດ ງ ອດ ອດ ສາງເຫ
Image 1: PTEI position (89,7	N gene at	the highligh	ted intronic		Total count: 31 A : 0 C : 2 (6%, 0+, 2- G : 0 T : 29 (94%, 0+, N : 0 DEL: 4 INS: 3	29-)







- c. Is this gene listed in OMIM (<u>http://www.ncbi.nlm.nih.gov/omim</u>)? if yes, does it have a reported relationship to your patient's diagnosis?
- d. Using Clinvar (http://www.ncbi.nlm.nih.gov/clinvar/)
 - 1. How many submissions are there for the image 1 and 2 variant?
 - 2. What is the reported clinical significance?
- e. Based on the criteria you listed, for the variant in each of the 2 images: a) Would you call this variant? Explain your answer in up to 2 sentences. b) Would you report the variant? Explain your answer in up to 2 sentences. If yes, also include up to 2 sentences of sample text explaining how you would report it.
 - 1. Image 1 variant
 - 2. Image 2 variant

3. The following germline results are obtained:

(Variant from exercise 1): (same as in exercise 1) RYR1: c. 1840C>T (p.Arg614Cys) CFTR: No variant detected

- a. Using OMIM, (<u>http://www.ncbi.nlm.nih.gov/omim</u>), list the disease(s) with which RYR1 is associated. (HINT: search using "ryr1")
- b. Using ClinVar (<u>http://www.ncbi.nlm.nih.gov/clinvar/</u>), is the RYR1 variant clinically significant? (HINTS: search using "1840c>t"; review any PubMed links)

Could consider another variant, malignant hyperthermia chosen as an incidental finding with specific significance for a number of specialties

c. Which of the results should the patient know about? Explain why, in up to 2 sentences for each result. (REVEAL)



d. The patient is known to have a *CFTR* variant. List 2 reasons why the variant may not have been detected using whole-exome sequencing. (REVEAL)

May consider another variant...this one chosen as one with significance for prenatal screening and the original patient was female